{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=10",
    "query": {
      "intervention": "dose level 1",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 29083,
    "total_pages": 2909,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T20:28:30.784Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01413178",
      "title": "A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myeloma"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire",
          "type": "OTHER"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "High Dose Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Stem cell transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 205,
      "start_date": "2011-09-30",
      "completion_date": "2019-03-10",
      "has_results": true,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-11-09T20:28:30.784Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01413178"
    },
    {
      "nct_id": "NCT07094685",
      "title": "Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Head and Neck Squamous Cell Carcinoma",
        "Resectable Head and Neck Squamous Cell Carcinoma",
        "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma",
        "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma",
        "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ivonescimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2025-11-18",
      "completion_date": "2030-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-11-09T20:28:30.784Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07094685"
    },
    {
      "nct_id": "NCT05704985",
      "title": "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Colorectal Cancer",
        "Pancreas Cancer",
        "Non Small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Gynecologic Cancer",
        "Skin Cancer",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "DK210 (EGFR)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Immune checkpoint blockers",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "DEKA Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2023-04-03",
      "completion_date": "2025-10",
      "has_results": false,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-11-09T20:28:30.784Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05704985"
    },
    {
      "nct_id": "NCT01285414",
      "title": "Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Verubulin",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide & Radiation Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myrexis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 5,
      "start_date": "2010-12",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2012-04-11",
      "last_synced_at": "2026-11-09T20:28:30.784Z",
      "location_count": 2,
      "location_summary": "Stanford, California • Houston, Texas",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01285414"
    },
    {
      "nct_id": "NCT00622414",
      "title": "Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ziv-aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 27,
      "start_date": "2008-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-02-24",
      "last_synced_at": "2026-11-09T20:28:30.784Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00622414"
    },
    {
      "nct_id": "NCT02316106",
      "title": "A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2015-05-20",
      "completion_date": "2024-06-03",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-11-09T20:28:30.784Z",
      "location_count": 15,
      "location_summary": "Little Rock, Arkansas • Jacksonville, Florida • West Palm Beach, Florida + 12 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02316106"
    },
    {
      "nct_id": "NCT01971047",
      "title": "Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Regular Insulin",
          "type": "DRUG"
        },
        {
          "name": "Humalog",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-10",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-11-09T20:28:30.784Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01971047"
    },
    {
      "nct_id": "NCT05443126",
      "title": "A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "EP0031",
          "type": "DRUG"
        },
        {
          "name": "Platinum chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ellipses Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 265,
      "start_date": "2022-09-30",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-09T20:28:30.784Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 16 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05443126"
    },
    {
      "nct_id": "NCT06619678",
      "title": "A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MK-8507",
          "type": "DRUG"
        },
        {
          "name": "Islatravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2024-01-17",
      "completion_date": "2024-06-23",
      "has_results": false,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-11-09T20:28:30.784Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06619678"
    },
    {
      "nct_id": "NCT01004185",
      "title": "Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Asacol 400 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Warner Chilcott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 39,
      "start_date": "2009-10",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2012-05-25",
      "last_synced_at": "2026-11-09T20:28:30.784Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01004185"
    }
  ]
}